News about Clinical Trials

Advarra Launches Comprehensive Solution to Improve Collaboration on Clinical Trials

The new offering combines the Longboat technology acquired by Advarra in 2020, which now has over 225,000 users, with Advarra's study startup delivery program and industry-adopted single sign-on capabilities.

Clinical Trials | 22/01/2025 | By Aishwarya |  856

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

The company successfully completed an FDA-recommended study of isomyosamine that demonstrated clinical safety throughout 13 weeks of treatment at all dose levels evaluated.

Clinical Trials | 16/01/2025 | By Aishwarya |  451

CARsgen Initiates Investigator-Initiated Trial for Allogeneic CD19/CD20 CAR-T Therapy

KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases.

Clinical Trials | 02/01/2025 | By Aishwarya |  467

CStone Submits Clinical Trial Application in Australia for CS2009

CS2009 features an innovative molecular design that targets PD-1, VEGFA, and CTLA-4 simultaneously, maintaining balanced affinity for PD-1 and CTLA-4.

Clinical Trials | 23/12/2024 | By Aishwarya |  240

Pharming Unveils Positive Topline Data in Pediatric Clinical Trial of Leniolisib

Pharming plans to include data from this 4-11-year-old trial in regulatory filings worldwide for the approval of leniolisib for pediatric patients with APDS, beginning in 2025.

Clinical Trials | 13/12/2024 | By Aishwarya |  327

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300

The enrollment of the first patient in Taiwan extends the recent expansion of the HARMONIC™ trial into Asia, where there is a notably higher prevalence of never-smoker NSCLC patients compared to Western populations.

Clinical Trials | 10/12/2024 | By Aishwarya |  267

Epigenic Therapeutics to Initiate Clinical Development of EPI-003

This first-in-human study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EPI-003 in Nucleos(t)ide Analogue-Treated, Chronic Hepatitis B Patients.

Clinical Trials | 20/11/2024 | By Aishwarya |  613

GlycoNex Signs Manufacturing Deal with Sterling for GNX102-ADC Clinical Trial Production

GNX102-ADC combines GlycoNex's proprietary monoclonal antibody (mAb), GNX102, and cytotoxic drug therapies to elicit cellular cytotoxicity to target cancer cells with high specificity.

Clinical Trials | 13/11/2024 | By Aishwarya |  314

Shuttle Pharma Finalizes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine

Ropidoxuridine (IPdR) is Shuttle Pharma's lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma), a deadly malignancy of the brain with no known cure.

Clinical Trials | 29/10/2024 | By Aishwarya |  295

Unravel Biosciences and PECET to Conduct Clinical Trials of RVL-001 in Rett Syndrome in Colombia

Unravel's proprietary BioNAV drug discovery platform identified RVL-001 as a potentially promising therapeutic drug for Rett Syndrome and PTHS.

Clinical Trials | 25/10/2024 | By Aishwarya |  437